Tak Wah Mak
Tak Wah Mak, (; born October 4, 1946, in China) is a Canadian medical researcher, geneticist, oncologist, and biochemist. He first became widely known for his discovery of the T-cell receptor in 1983 and pioneering work in the genetics of immunology. In 1995, Mak published a landmark paper on the discovery of the function of the immune checkpoint protein CTLA-4, thus opening the path for immunotherapy/checkpoint inhibitors as a means of cancer treatment. Mak is also the founder of Agios Pharmaceuticals, whose lead compound, IDHIFA®, was approved by the FDA for acute myeloid leukemia in August 2017, becoming the first drug specifically targeting cancer metabolism to be used for cancer treatment. He has worked in a variety of areas including biochemistry, immunology, and cancer genetics. Provided by Wikipedia-
1by Gerry Melino, Francesco Cecconi, Pier Giuseppe Pelicci, Tak Wah Mak, Francesca BernassolaGet full text
Published 2019-10-01
Article -
2
-
3by Parag Kundu, Teo Wei Ling, Agata Korecka, Yinghui Li, Rossana D'Arienzo, Ralph M Bunte, Thorsten Berger, Velmurugesan Arulampalam, Pierre Chambon, Tak Wah Mak, Walter Wahli, Sven PetterssonGet full text
Published 2014-01-01
Article -
4by Bin Jiang, Jia Zhang, Jinmei Xia, Wentao Zhao, Yanan Wu, Minggang Shi, Lianzhong Luo, Huamin Zhou, Ai Chen, Huanhuan Ma, Qingwen Zhao, Muhammad Suleman, Furong Lin, Lin Zhou, Jinyang Wang, Yan Zhang, Ying He, Xiaotong Li, Li-Man Hung, Tak Wah Mak, Qinxi LiGet full text
Published 2017-04-01
Article -
5by Xiaohui Wang, Xiang Lin, Zihan Zheng, Bingtai Lu, Jun Wang, Andy Hee-Meng Tan, Meng Zhao, Jia Tong Loh, Sze Wai Ng, Qian Chen, Fan Xiao, Enyu Huang, King-Hung Ko, Zhong Huang, Jingyi Li, Kin-Hang Kok, Gen Lu, Xiaohui Liu, Kong-Peng Lam, Wanli Liu, Yuxia Zhang, Kwok-Yung Yuen, Tak Wah Mak, Liwei LuGet full text
Published 2021-03-01
Article